← Back to Search

Collaborative Decision Skills Training for Mental Illness (CDST Trial)

N/A
Recruiting
Led By Emily B Treichler, PhD
Research Sponsored by VA Office of Research and Development
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
having primary substance use or organic neurological disorder diagnosis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change in consumer driven collaborative behaviors from baseline (month 0) to follow-up at 3-months post-intervention (month 5)
Awards & highlights

Summary

This trial will establish the feasibility of Collaborative Decision Skills Training (CDST) among 12 Veterans with serious mental illness (SMI), and compare it to active control (AC) using a randomized clinical trial of 72 Veterans.

Who is the study for?
This trial is for Veterans with serious mental illnesses like schizophrenia and major depressive disorder, who are currently receiving services at the VA San Diego Psychosocial Rehabilitation and Recovery Center. Participants must be willing to have some treatment sessions recorded. Those with high violence risk or primary substance use disorders cannot join.
What is being tested?
The study tests Collaborative Decision Skills Training (CDST), aiming to empower Veterans by improving their decision-making skills in treatment settings. It involves an initial feasibility phase followed by a randomized trial comparing CDST against an active control through group sessions over eight weeks.
What are the potential side effects?
Since this intervention focuses on skill training rather than medication, traditional side effects are not expected. However, there may be psychological discomfort from engaging in new types of interactions or discussing sensitive topics during training.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have been diagnosed with a substance use or brain disorder.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change in goal attainment from baseline (month 0) to follow-up at 3-months post-intervention (month 5)
This trial's timeline: 3 weeks for screening, Varies for treatment, and change in goal attainment from baseline (month 0) to follow-up at 3-months post-intervention (month 5) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Shared Decision-Making Coding System
Secondary study objectives
Brief Psychiatric Rating Scale
Canadian Occupational Performance Measure- Performance subscale
Client Satisfaction Questionnaire
+14 more
Other study objectives
Acute service use
Adaptation and implementation focused qualitative interviews
CDST Participant Satisfaction Questionnaire
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Collaborative Decision Skills TrainingExperimental Treatment1 Intervention
Collaborative Decision Skills Training (CDST) is the intervention group (experimental arm).
Group II: Leveling UpActive Control1 Intervention
Leveling Up is the active control arm.

Find a Location

Who is running the clinical trial?

VA Office of Research and DevelopmentLead Sponsor
1,647 Previous Clinical Trials
3,359,998 Total Patients Enrolled
44 Trials studying Schizophrenia
5,092 Patients Enrolled for Schizophrenia
Emily B Treichler, PhDPrincipal InvestigatorVA San Diego Healthcare System, San Diego, CA
Emily Treichler, PhDPrincipal InvestigatorVA San Diego Healthcare System, San Diego, CA

Media Library

Collaborative Decision Skills Training Clinical Trial Eligibility Overview. Trial Name: NCT04324944 — N/A
Schizophrenia Research Study Groups: Leveling Up, Collaborative Decision Skills Training
Schizophrenia Clinical Trial 2023: Collaborative Decision Skills Training Highlights & Side Effects. Trial Name: NCT04324944 — N/A
Collaborative Decision Skills Training 2023 Treatment Timeline for Medical Study. Trial Name: NCT04324944 — N/A
~10 spots leftby Jan 2025